Acquisition - April 1, 2026
Eli Lilly and Company to acquire Centessa Pharmaceuticals
Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to treat excessive daytime sleepiness and disorders of impaired wakefulness.
Acquisition - April 1, 2026
Biogen to acquire Apellis Pharmaceuticals
The two companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for USD 41.00 per share in cash at closing, or approximately USD 5.6 billion.
Acquisition - March 30, 2026
Insilico Medicine and Lilly enter R&D collaboration
Insilico Medicine has announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.
Global report - March 30, 2026
Scientists Fighting Back
Many observers and most of the scientific community agree; the outlook for scientific research in the US has never been more uncertain.
Acquisition - February 9, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease.
Global report - February 9, 2026
Innovent and Lilly in strategic collaboration
Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology.
